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Abstract: Surgeons rely almost completely on their own vision and palpation to recognize affected
tissues during surgery. Consequently, they are often unable to distinguish between different cells
and tissue types. This makes accurate and complete resection cumbersome. Targeted image-guided
surgery (IGS) provides a solution by enabling real-time tissue recognition. Most current targeting
agents (tracers) consist of antibodies or peptides equipped with a radiolabel for Positron Emission To-
mography (PET) and Single Photon Emission Computed Tomography (SPECT), magnetic resonance
imaging (MRI) labels, or a near-infrared fluorescent (NIRF) dye. These tracers are preoperatively
administered to patients, home in on targeted cells or tissues, and are visualized in the operating
room via dedicated imaging systems. Instead of using these ‘passive’ tracers, there are other, more
‘active’ approaches of probe delivery conceivable by using living cells (macrophages/monocytes,
neutrophils, T cells, mesenchymal stromal cells), cell(-derived) fragments (platelets, extracellular vesi-
cles (exosomes)), and microorganisms (bacteria, viruses) or, alternatively, ‘humanized’ nanoparticles.
Compared with current tracers, these active contrast agents might be more efficient for the specific
targeting of tumors or other pathological tissues (e.g., atherosclerotic plaques). This review provides
an overview of the arsenal of possibilities applicable for the concept of cell-based tracers for IGS.
Keywords: cell-based imaging; near-infrared; nuclear imaging; magnetic resonance imaging; leuko-
cyte; mesenchymal stromal cell; platelets; extracellular vesicle; microorganisms; nanoparticle
1. Introduction to Image-Guided Surgery
Although recent developments in laparoscopic and robotic surgery enable more
precise and less destructive operations, these techniques also deprive surgeons from
palpation, which is the second-most valuable source of information after visualization.
The intraoperative molecular imaging of lesions, which is used in image-guided surgery
(IGS), can partially compensate this loss and has already been proven valuable in both
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oncologic and vascular surgery [1,2]. As an example, during oncologic surgery, IGS might
not only help to identify tumor borders, recurrence, and metastases, but also provide
more insight in tumor composition, improving the differentiation between healthy and
malignant tissue [1]. Analogously, for vascular applications, near-infrared fluorescence
(NIRF) is especially promising in the visualization of skin perfusion in patients with severe
types of peripheral artery disease [2].
The majority of IGS approaches uses a cell-specific targeting agent equipped with
a NIRF dye or radiolabel and are used in conjunction with dedicated imaging systems.
The radiotracers may be visualized using Positron Emission Tomography (PET) or Single
Positron Emission Computed Tomography (SPECT). In the past years, clinical studies have
shown that real-time IGS improves the recognition of tumor tissue significantly, especially
in cases of challenging visual inspection and palpation [3,4].
Most of the current IGS tracers are based on monoclonal antibodies, peptides, or
aptamers, which are equipped with a NIRF dye (λ emission and λ absorption ranging from
700 to 900 nm). These so-called targeted tracers rely on binding to their tumor-associated
target after passive tissue diffusion and are a considerable improvement compared to the
first generation of tracers, which consisted basically of non-targeted dyes [5,6]. Positive
clinical oncologic IGS results have been obtained with various tracers targeting tumor-
associated proteins, including adhesion molecules such as integrins, tyrosine kinase recep-
tors such as vascular endothelial growth factor receptor (VEGFR), epidermal growth factor
receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and receptor ligands
such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and
folate [7–9]. However, immunohistochemical evaluation of resected tumors has shown that
the malignant cells are not always equally occupied with the tracer. Therefore, distribution
throughout the tumor can be heterogeneous, superficial, or patchy [10]. This phenomenon
is partly due to the physiological traits of the tracer (e.g., affinity, size, and charge), but it is
most likely also related to the characteristics of the lesion. For example, the presence of
angiogenic endothelial cells and other stromal cells can strongly influence the diffusion
of a tracer through the targeted tissue. An alternative approach to these imaging agents
for targeted but otherwise passive strategies would be the use of tracers that are able to
actively recognize and penetrate tissues, irrespective of the presence of a single protein on
the targeted cells or the presence of less permeable stroma. This is exactly how certain cell
types and cell-derived particles naturally behave in response to the presence of specific
chemokines excreted by the targeted cells in pathological lesions. Next to cancer, cell-based
carriers may be applied in cardiovascular lesions. For instance, preoperative imaging
of atherosclerotic plaque activity or instability could be employed to guide the decision
of (non-)operative treatments. Furthermore, the progression of (neo)intimal hyperplasia,
plaque vulnerability, and vein graft infections could be monitored to schedule timely
interventions and prevent further disease progression [11–13].
Although holding promise for the treatment and visualization of various diseases, the use of
cells for therapy or imaging in clinical applications still must overcome some serious obstacles. Issues
considering safety, reproducibility, scalable manufacturing systems, and not in the least the costs will
have to be solved. Current developments in cell-based vehicles are frequently based within the field
of drug delivery, yet many of the desired characteristics and features overlap with those needed in
the field of imaging [14]. In this review, we intend to give a comprehensive overview of possible
approaches for the use of cell-based carriers for IGS. The main characteristics determining the choice
of future cell-based IGS tracers are compiled in Table 1 and will be discussed accordingly in the
various sections. The possibilities of cells as active imaging tracers will be presented in the context of
IGS in Section 2, which are accompanied by their associated trafficking mechanisms. A comparable
phenomenon by which microorganisms travel to their preferred target tissues and their potential use
in IGS will be covered in Section 3. The fourth and last section will concisely focus on nanoparticles,
comparing these synthetic alternatives with cell- and microorganism-based carriers. In view of the
rapid advances in the field, this review will mainly address the imaging of tumors, but wherever
appropriate, examples of cell-based imaging strategies of cardiovascular diseases will be integrated.
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2. Cell-Based Carriers for IGS
Various types of human cells are naturally equipped to migrate actively in the direction
of certain parts of the body in response to chemotactic substances such as chemokines,
leukotrienes, eicosanoids, and reactants of the complement cascade [15]. Particularly, cells
from either the innate immune system (e.g., monocytes/macrophages, neutrophils) or
adaptive immune system (e.g., T cells, B cells) are commonly found within wounds,
inflammation sites, cardiovascular lesions, and almost any solid tumor, as schematically
indicated in Figure 1 [16,17]. In addition, mesenchymal cells (i.e., fibroblasts) and platelets
are also commonly found in the activated stroma of most pathological lesions [18,19].
Due to the active recruitment of immune cells to tumor sites, recent studies have evaluated
the concept of cells as vehicles for the delivery of therapeutic agents, such as the use
of macrophages to target human prostate tumor xenografts in a mouse model [20,21].
Similarly, NIRF- or radiolabeled versions of these cells should be able to reach tumors
actively via the circulation and might therefore be more efficient than the commonly used
‘passive’ targeted agents [22,23]. Labeled circulating cells could in principle out-perform
targeted proteins and nanoparticles, as they are physiologically more adapted to actively
penetrate tissues such as tumors and vascular lesions. The most obvious cells making use of
their natural asset of rapid tissue penetration are neutrophils, macrophages/monocytes, T
cells, and natural killer (NK) cells, but circulating platelets and mesenchymal stromal cells
are also known to migrate toward wound healing, inflammatory, and tumor sites [22,24].
In order to consider any type of cell as a targeted imaging agent, it should be taken into
account that retrieval and subsequent ex vivo labeling of these cells should not change the
cells’ properties. Therefore, it is important to design and employ strict regulations for the
implementation of all cell-based tracers, ensuring (i) precise knowledge of the effects of
cell modifications, (ii) prevention of any type of alteration in cell property or biological
behavior that might negatively affect patients, and (iii) preservation of the cell’s targeting
and imaging capabilities.
 
Figure 1. Distribution of cell types within a typical human colon tumor. Colors indicate respectively
malignant epithelial cells (gray), immune cells (CD45, red), fibroblasts (fibroblast activation protein,
blue), and endothelial cells (CD31, green), as stained in a multiplex analysis using a 40× field.
Adapted from Sandberg et al. with permission [25].
2.1. Leukocyte-Based IGS Carriers
Circulating leukocytes form an essential component of the immune system and there-
fore are particularly equipped to reach any site of the body as part of the natural defense.
They are commonly classified into two classes, which are based on cellular lineage: myeloid
(i.e., granulocytes, monocytes, and macrophages) and lymphoid (i.e., T cells, B cells, and
Natural killer cells).
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2.1.1. Monocyte/Macrophage-Based IGS Carriers
Macrophages and their progenitors, monocytes, are important cell types for antigen
presentation to lymphocytes and play a key role as effector cells in immune responses.
Although they are among the largest in diameter (16–22 µm) (Figure 2 and Table 1),
these cells are remarkably flexible and able to penetrate into almost any tissue of the
human body. They have strong tumor-homing ability because they are attracted by chronic
inflammation, hypoxia, and by tumor cells in response to a gradient of chemo-attractants.
An example of a potent chemokine in the attraction of monocytes to tumor sites is monocyte
chemoattractant protein-1 (MCP-1, also known as CCL2). This chemokine, produced by
malignant tumor cells as well as by stromal cells, contributes to tumor progression [26].
There is an ongoing discussion on the subdivision of macrophages into subtypes with
varying characteristics [27]. In general, these cells can be polarized into an inflammatory or
tissue repair subtype, with respectively tumor-attacking and tumor-promoting properties.
Upon arrival in the tumor microenvironment, they play an active role in various stages
of tumor progression: from early carcinogenesis to metastasis [28]. Macrophages also
play an important role in cardiovascular diseases and are especially known for their role
in atherosclerosis [29].
Macrophages and monocytes could be attractive candidates for IGS, provided that
they can be isolated from the circulation, conveniently labeled, and that only the appro-
priate macrophage type would be used for the desired application. In an example of
manipulating macrophage motility, Muthana et al. have demonstrated that magnetically
labeled macrophages can be selectively guided to prostate tumors in mice, using a magnetic
resonance imaging (MRI) system and pulsed magnetic field gradients [30]. This concept
can be extended to the use of different imaging labels such as NIRF- or radiolabeled dyes.
In this context, Fu J. et al. have shown that murine macrophage-like cells (RAW264.7 cell
line) can be readily labeled with the NIRF dye DiR (KGMP0026) in only 30 min of incuba-
tion [31]. Likewise, monocytes isolated from the circulation of patients could be labeled
with clinically established NIRF dyes such as indocyanine green (ICG) or IRDye 800CW.
Given that macrophages can cross the blood–brain barrier and have already been proposed
as targeted drug delivery vehicles [32], one possible application of labeled macrophages as
described above would be facilitating the excision of gliomas by IGS. In fact, PET and MRI
imaging have been widely combined for visual tracking of tumors and atherosclerotic le-
sions, using tracers that largely target activated macrophages. For instance, the non-specific
probe 18F-Fluorodeoxyglucose (18F-FDG) has been used in oncology for monitoring and
staging of cancers and for the assessment of atherosclerotic plaques using PET [33,34].
As indicated, before advocating the implementation of macrophages in IGS, a point
of attention is the polarization of macrophage subtypes and their biological role in patho-
logic lesions. M1 macrophages are associated with infectious and inflammatory diseases,
atherosclerosis, and an anti-tumor role, whereas M2 macrophages are associated with an
anti-inflammatory role, supporting pro-tumor conditions. Using macrophages for IGS
in oncology would require strict control over the type of macrophage used to avoid any
unwanted activities that could (i) favor tumor growth, proliferation, and survival and (ii)
induce severe side effects. Although a consensus has yet to be reached on what character-
izes the terminal stage of macrophage differentiation, it is often thought that macrophages
are terminally differentiated and therefore cannot be expanded. Accordingly, the isola-
tion of macrophages from patients for IGS applications would require leukapheresis and
elutriation to ensure a sufficient quantity of cells [35].
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Figure 2. Schematic overview of cell- and nanoparticle-based IGS tracers in a blood vessel near tumor tissue. Sizes of
possible IGS tracers differ substantially. Logically, they rely on different mechanisms to reach their target tissue.
To summarize, macrophages are attractive candidates as cell-based tracers for IGS
in oncology, owing to their tumor-homing capacity, localization in the tumor microenvi-
ronment, stealth in blood circulation as monocytes, and to the relative ease with which
they can be isolated and labeled with NIRF dyes. In addition, macrophages are abundantly
present in cardiovascular lesions and important drivers of atherosclerotic disease. There-
fore, they could be targeted in the context of grading and monitoring disease progression.
However, macrophage subtypes and possible negative functional changes during cell alter-
ations should be carefully considered. Especially in the context of IGS in oncology, only
macrophages with tumor-attacking characteristics should be used. Given these reasons,
macrophages should be further explored as tracers for IGS.
2.1.2. Neutrophil-Based IGS Carriers
Neutrophils constitute roughly half of the white blood cells in the body, have a di-
ameter of 9–15 µm, and are the first immune cells to respond to tissue injury or infection
sites [36]. Similar to macrophages, neutrophils are actively recruited by chemo- and
cytokines that are produced in inflammatory environments, including tumor microenvi-
ronments and atherosclerotic plaques [37]. Activated neutrophils use adhesive molecules
such as selectins to adhere to vessel walls, after which they transmigrate to reach the site
of destination. In this context, Wang et al. discovered that albumin nanoparticles, loaded
with the far-red-fluorescent dye Cyanine 5 (Cy5), were internalized by activated, adherent
neutrophils in tumor necrosis factor α (TNFα)-challenged mouse cremaster post-capillary
venules [38]. Real-time fluorescence showed that 95% of the Cy5-labeled or -conjugated
albumin nanoparticles had been internalized by the adherent neutrophils, whereas none of
the control particles (albumin-conjugated polystyrene particles or Cy5-conjugated albumin)
had been internalized. Furthermore, based on nanoparticle internalization experiments
using FcγRIII−/− and wild-type mice, the authors discovered that the FcγRIII receptor
contributed to approximately 50% of total albumin nanoparticle internalization by neu-
trophils [38]. Their findings suggest that in terms of fluorescent imaging, the FcγRIII
receptor on activated neutrophils could be exploited for labeling and tracking the neu-
trophils themselves as well as for delineating the targeted inflammatory site to which these
neutrophils ultimately migrate.
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Neutrophils have also been harnessed for application in computed tomography (CT)
and SPECT imaging. For example, it is feasible to radiolabel autologous neutrophils and to
quantify neutrophil accumulation in the lungs of human chronic obstructive pulmonary
disease (COPD) patients [39]. Technetium-99m-hexamethylpropyleneamine oxime was
used as a radiolabel, and a high rate of reproducibility of the resultant signal among
patients at t = 7–10 days was found. Similar to macrophages, neutrophils can cross the
blood–brain barrier, enabling them to penetrate brain tissue and target gliomas in mice [40].
Vaas et al. labeled neutrophils with the NIRF tracer LIPO-6S-IDCC, using them for non-
toxic intraoperative imaging of brain tumors in mice [41].
In addition to different imaging and labeling applications, neutrophil isolation should
be considered. A common misconception is that (labeled) neutrophils generate the majority
of the imaging signal, as they are the most common cell type among blood granulocytes.
This idea might interfere with precise imaging of the target lesion, as it has been shown
that eosinophils in the granulocyte population tend to be radiolabeled with significantly
higher efficiency and have a different biodistribution compared to neutrophils [42,43].
The latter is especially important in individuals with inflammatory conditions that involve
the upregulation of eosinophils, such as asthma and esophagitis. In this context, the anti-
CD16-conjugated magnetic beads approach by Lukawska et al. might be adopted, which
allows for the separation of blood eosinophil and neutrophil granulocytes in a human
venous blood sample while conserving their migratory phenotype upon intravenous
reinfusion [43]. Another issue to consider is that neutrophils are relatively fragile, become
easily activated, and die rapidly, which might be a complication for practical use.
Similar to macrophages, neutrophils offer functional advantages that make them
attractive tracers for IGS, including their natural abundance in the blood and active homing
capabilities. Nonetheless, crucial elements to consider are the accuracy of neutrophil
acquisition, the fragility of neutrophils, and the possible alterations of biological properties
upon (minimal) stimulation and labeling.
2.1.3. T Cell-Based IGS Carriers
T lymphocytes or T cells (diameter = 6–12 µm; Figure 2 and Table 1) are specialized in
the tracking and killing of cells that express foreign peptides. As critical components of
adaptive immunity, T cells perform specialized functions such as the tracking or killing of
foreign cells, activation of immunological memory against previously confronted antigens,
and the suppression of immune responses to prevent autoimmunity. The vigorous infiltra-
tion of certain T cells in tumor lesions has been correlated to a positive prognosis in several
cancer types, including bladder cancer, metastatic melanoma, ovarian cancer, and renal
cell carcinoma [44,45]. In a meta-analysis on the presence of CD3+, CD4+ (helper or “Th”),
CD8+ (cytotoxic), or FoxP3+ (regulatory) T cells in solid tumors, Gooden et al. concluded
that a high ratio of CD8+ to FoxP3+ T cells, and the presence of both CD3+ and CD8+,
each correspond to higher survival rates [46]. High numbers of especially CD8+ T cells are
an indication of beneficial immunogenicity, which can result in an improved response to
immunotherapies and a more favorable prognosis [45]. Additionally, the presence of Th1
cells, a subtype of CD4+ T cells, is a positive prognostic factor for cancer patients [47].
T cells are currently being explored for targeted tumor imaging and therapy [48].
Chimeric antigen receptor (CAR)-T cells are especially interesting. CAR-T cells are T cells
that are genetically modified to express a recombinant antigen recognition domain to
optimize the targeting of a patient’s tumor cells. These CAR-T cells are manipulated and
expanded ex vivo and subsequently administered to patients. CAR-T cells can be prepared
in various ways, either of which is biocompatible; The currently FDA-approved CAR-T cell
therapies are based on autologous CAR-T cells, in which the original (unmodified) T cells
originate from the patient. However, there are increasing efforts at developing allogenic
CAR-T cells, which are manufactured in large batches and may be used in multiple patients.
The major drawback of autologous CAR-T cells is that the acquisition and manipulation of
these cells is both time-consuming and expensive. Additionally, problems may arise due to
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off-target responses such as cytokine release syndrome (treatable with tocilizumab [49])
and neurotoxicity [50]. Moreover, there is a paucity of validated standardized tools for
qualifying the potency of CAR-T cells [51].
Interestingly, cytotoxic T cells (also known as cytotoxic T lymphocytes (CTLs)) can be
functionalized with nanoparticles for applications in tumor imaging and therapy. For in-
stance, Jones and colleagues prepared nanocapsule-CTL conjugates and tested them as
agents for the targeted delivery of immunotherapy to an anatomic site of viral replication
in HIV-infected humanized mice [52]. Intriguingly, drug release from these nanocapsules
is triggered by specific stimulation of the T cell receptor. By extension, one could merge the
tumor-homing properties of CAR-T cells with NIRF dye-labeled or radiolabeled nanoparti-
cles to generate a hybrid nanoparticle/CAR-T tracer. Although we have mostly focused
on the imaging of tumors and the tumor microenvironment, there are characteristics of T
cells that make them potentially useful for other IGS applications in oncology. For example,
tumor-egressing T cells have been shown, in a mouse model, to disseminate to distant
tumors and draining lymph nodes, mediating anti-tumor responses at sites of metastasis;
Accordingly, a tracer such as the NIRF dye- or radiolabeled nanoparticle/CAR-T hybrid
described above might be useful for imaging lymph nodes and distal metastases [53].
On the whole, (CAR-)T cells offer numerous characteristics that suggest their utility
for IGS. The combination of their specificity and biocompatibility has great potential,
provided that progress will be made regarding the efficiency and costs of T cell acquisition.
For successful clinical translation, it is essential that cell-based issues such as unintended
altered functions and off-target responses will be controlled or avoided.
2.1.4. NK Cells-Based IGS Carriers
Natural killer (NK) cells, which are subsets of lymphocytes, play an important role
in the innate immune system by killing target cells without the need of immunization or
prior sensitization. They have a relatively small diameter (6–7 µm) in comparison to other
immune cells (Figure 2 and Table 1). To control their cytotoxicity in healthy tissue, inhibitory
receptors on the surface of NK cells constrain their activation upon recognition of major
histocompatibility complex (MHC) class-I receptors on healthy, nucleus-containing cells.
When MHC I expression is absent or abnormal, which commonly occurs in infected cells or
cancer cells, the inhibitory signals are lost, and the target cell is killed via a system of lytic
granules containing granzymes and perforin proteins [54,55]. In addition to this function,
NK cells are known to be involved in modulating both innate and adaptive immune
responses through the production of cytokines such as TNFα, interferon γ, macrophage
inflammatory protein (MIP)-1α, and MIP-1β [56].
Recently, CAR-NK cells have been described as potent tumor-targeting cells in the
context of both direct NK cell-mediated cytotoxicity and the indirect use of NK cells as
anti-tumor drug carriers [57,58]. Similar to the concept of the previously described CAR-T
cells, CARs are added to the cell membrane of NK cells, improving their tumor-homing
abilities. Despite their similarity, these CAR-NK cells have some important advantages
compared to CAR-T cells. Firstly, due to their shorter circulation lifetime and less aggressive
cytokine release spectra, CAR-NK cells are less associated with harmful side effects such
as neurotoxicity and cytokine release syndrome [58,59]. Moreover, to prevent unwanted
in vivo proliferation and persistence, NK cells may be irradiated prior to their clinical
application [60,61]. Secondly, the use of allogeneic NK cells is less associated with graft-
versus-host-disease, allowing for the use of unlimited allogeneic sources such as induced
pluripotent stem cells, human embryonic stem cells, umbilical cord blood, peripheral blood
mononuclear cells, and NK-92 cells [62–64]. The latter is an immortal cell line, originating
from an NK cell lymphoma patient, that is easily modified, expanded, and stored under
conditions of good manufacturing practice. Thirdly, it is estimated that, whereas the
preparation and administration of CAR-T cells in cancer immunotherapy may cost up
to 250,000 dollars, engineered NK-92 infusion cycles commonly cost less than 20,000
dollars [65].
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Next to the apparent potential of CAR-NK cells for IGS, several limitations should
be considered. The largest challenge of CAR-NK cells is the genetic transfection method
for engineering NK cells to express CAR receptors. The predominant techniques use lenti-
or retroviral gene transduction, but these methods are respectively lacking in terms of
efficiency and the possibility of inducing insertion mutations [66,67]. However, it should
be noted that developments in this field will in all probability lead to the standardization of
more efficient gene transduction methods in the near future [68]. Since the research field of
CAR-NK cells is relatively novel as compared to CAR-T cells, most of the current CARs are
specifically designed for the latter cell type. Applying these CARs in the context of NK cells
might result in general inefficiency and negative alterations in cell properties. Specific CAR-
NK cell constructs should be adopted for IGS purposes, such as in the approach of Li et al.,
who established CAR-NK cells to target melanomas [63].
In the context of IGS, it is feasible to construct aptamer-engineered hepatocellular
carcinoma-specific NK cells that are labeled with ICG and allow for effective imaging in
mice [69]. These aptamers, single-stranded oligonucleotides, are designed to specifically
recognize and bind their targets. As described by Yang et al., the generation of aptamer-NK
cells is straightforward, has a high yield, does not alter cellular properties, and can be
carried out within 30 min [70]. MRI imaging of NK cells in vivo has mainly been achieved
with the use of superparamagnetic iron-oxide nanoparticles. For instance, the visualization
of NK-92 cell lines with superparamagnetic iron-oxide ferucarbotran and ferumoxide was
studied by Daldrup-Link et al., showing that genetic modification steps enabled CAR-
specific targeting of tumor-associated HER2/neu positive mammary tumors in mice [71].
A more recent study confirmed the clinical feasibility of this technique by labeling murine
NK cells with a nanocomplex consisting of heparin, protamine, and ferumoxytol (HPF) to
visualize NK cell distribution in a rat model of hepatocellular carcinoma [72]. The biodis-
tribution of both autologous and allogenic in vitro cultured NK cells, radiolabeled with
indium-111 oxine, has been investigated in patients with renal cell carcinoma and liver
metastases respectively and showed the feasibility of SPECT imaging [73,74]. Next to this,
an in vivo antibody-mediated approach was reported by Galli et al., which might overcome
issues of indium-111 oxine regarding NK cell viability [75]. They radiolabeled an anti-CD56
monoclonal antibody with technetium-99m that subsequently targeted and imaged NK
cells in SCID mice that bore human anaplastic thyroid cancer cells. Meier and colleagues
showed that labeling of CAR-NK-92 cells with the PET tracer 18F-FDG allowed for the
imaging of implanted HER2/neu-positive tumors in mice at 60 minutes after injection [76].
In summary, (CAR-)NK cells demonstrate promising characteristics as carriers for
IGS. CAR-NK cells show less toxicity and graft-versus-host-disease than their CAR-T
cell counterparts, are relatively inexpensive to generate, and can be engineered to be
highly specific for target tissue. Necessary for the translation of CAR-NK cells to the
clinic are advancements in the transduction of CAR genes to increase efficiency and avoid
genotoxicity. Moreover, the development of specific CAR constructs for the purpose of
CAR-NK cell-based IGS should be encouraged.
2.2. Platelet-Based IGS Carriers
Platelets, also known as thrombocytes, are nucleus-free living cell fragments that
are primarily present in blood vessels. With an estimated diameter of 1–3 µm (Figure 2
and Table 1), they are smaller than any of the immune cells presented above, facilitating
tissue penetration. A human adult can produce up to 5 × 1011 platelets a day and main-
tains a concentration of (150–400) × 103 per µL blood, in contrast to about (4–10) × 103
leukocytes per µL blood [77–79]. Platelets are mostly known for targeting vascular lesions,
but they also bind to tumor-associated proteins such as fibrinogen, collagens, and inte-
grins. They commonly accumulate in the tumor microenvironment in a process called
extravasated platelet aggregation, especially at sites of neoangiogenesis and invasive bor-
ders [80–83]. Platelets are also found on invading and circulating tumor cells, where they
play a role in the stimulation of the epithelial-to-mesenchymal transition status of these
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cells and are associated with chemoresistance [83]. Moreover, platelets can facilitate can-
cer progression by secreting angiogenesis-inducing bioactive lipids and proteases upon
activation by tumor cells [84]. In the context of platelet transfusion for donor-dependent
thrombocytopenic patients, the ex vivo storage and generation of thrombocytes has been
extensively studied. Prepared platelets that have been transfused within 24–48 h exhibit
good survival rates, recovery, and function [85]. The addition of platelet additive solutions,
the use of technologies that remove pathogens, and advances in automation have led
to further extension of possible storage times. However, this gain in storage time was
at the cost of a rapid decrease in quality and nonviability of platelets after five to seven
days [85,86]. Platelets can be produced using stem cells of diverse origins by generat-
ing mature megakaryocytes ex vivo and subsequently injecting them into experimental
subjects based on the process of platelet production in pulmonary capillary beds [77,87].
However, in either case, megakaryocyte maturation and megakaryocyte platelet release
still need to be optimized, especially considering the cost of current techniques [87].
Among the main advantages of platelets as candidates for IGS tracers is that they
have privileged access to the deepest parts of the body. Platelets gain access to patho-
logic microenvironments through passive diffusion across pores in surrounding vessels.
For example, platelets have demonstrated potential as delivery systems to penetrate the
blood–brain barrier for the treatment of malignant glioblastomas and ischemic strokes [88].
The former, being the most common and aggressive form of primary brain tumors, is
initially treated with surgery [89]. Intraoperative imaging, using modalities such as MRI,
PET, and CT, is necessary to reach maximal resection of the primary tumor [90,91]. It is
evident that a combination of radiolabeled platelets in combination with PET-CT or SPECT-
CT could improve upon existing imaging techniques for staining tumor tissue and thus
ameliorate the accuracy of surgical treatment. In addition, the in vivo lifetime of platelets
is perfectly suited for imaging, with a survival time of seven to ten days and a circulation
time up to nine days in humans, compared to only about 3 to 9 h of circulation time of
nanoparticles [78,92]. This is important, since a longer survival time increases the chance
of encountering tumor cells. Moreover, given their size of about 2 µm, which is larger than
most synthetic nanoparticles (Figure 2), they are less likely to be purged by scavenging
macrophages and liver cells. Together, these factors should allow for excellent penetration
at the target site and, consequently, suggest that platelets are strong candidates for imaging
purposes. In fact, there is a history in such applications.
Fluorescently labeled platelets have been introduced by Horne in 1975, followed by
multiple other groups with studies on similar systems, in which various fluorophores
have been coupled to the membranes of platelets [92–94]. In the context of a dye-carrying
approach, platelets may release their dye in a very controlled manner upon reaching
their target, due to the earlier mentioned cancer cell-induced platelet activation. Inter-
estingly, this mechanism can be exploited by manually inducing a release of platelet
contents, as demonstrated by Sarkar et al., potentially leading to strong local effects [93].
Similarly, platelets could be engineered to carry NIRF dyes or radioactive tracers and specif-
ically release those at target sites. In addition, platelets can also be marked with radiolabels
at ligand-induced binding sites—epitopes that bind to single-chain antibodies. For instance,
a single-chain antibody, targeting the activated integrin αIIbβ3 on platelets and labeled
with Indium-111, was used in an in vivo carotid artery thrombosis mouse model to detect
wall-adherent activated platelets by using SPECT-CT [95]. Furthermore, another clinically
attractive feature of platelets is that they can be quickly adapted for imaging; Repurposing
freshly acquired platelets into usable imaging vehicles can typically be completed within 60
minutes, especially when automated [92]. Finally, from a clinical point of view, the imaging
of activated platelets could be used in the monitoring of plaque stability within the fields
of carotid and heart surgery.
Despite the aforementioned advantages of platelets, there are some disadvantages to
consider. Platelets are known to aggregate easily in response to several chemical and phys-
ical conditions required for their repurposing [96,97]. One solution to this problem is to
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incubate the platelets with kabiramide, which is a potent inhibitor of actin polymerization
that prevents aggregation [92]. Another point of concern is that the tumor cell-mediated
activation of platelets may lead to platelet–tumor cell aggregates, which would then shield
the tumor cells from the immune system and facilitate metastatic spread [98]. Addition-
ally, thrombocytes have been shown to induce (primary) tumor growth, cell invasion,
and epithelial-to-mesenchymal transition, and they are able to promote angiogenesis and
tumor cell settlement at distant sites [98,99]. However, although platelets can facilitate
cancer in these ways, the number of platelets used for imaging would be negligible in
contrast to the total number that is already circulating, especially considering their circula-
tion lifetime.
Conclusively, human platelets seem appealing candidates for imaging applications.
Considering the short time required to repurpose them into imaging vehicles, their
widespread availability in the circulation, and their tissue-penetrative capabilities, platelets
could serve as excellent cell-based tracers for IGS. Nevertheless, in order to facilitate a
translation to the clinic, further research is needed to elucidate the extent and effects of
platelet–tumor cell interactions, ensure patient safety, and optimize and standardize pro-
duction processes. Moreover, an important first step should be to assess the different
concepts of platelet-based imaging: (i) labeled platelets accumulating in target tissue and
(ii) platelets releasing specific dyes at targeted sites.
2.3. Mesenchymal Stromal Cell-Based IGS Carriers
Mesenchymal stromal cells (MSCs), which have already shown therapeutic promise
in inflammatory and degenerative diseases, have recently emerged as cell-based (drug) car-
riers [100,101]. MSCs are multipotent cells that exhibit fibroblast-like morphology and can
differentiate into adipocytic, myogenic, osteogenic, and chondrogenic lineages [101,102].
The minimal criteria for the definition of human MSCs, as defined by the International
Society for Cell therapy, are very broad, leaving room for different interpretations and, con-
sequently, heterogeneous reports of cell types [100,103]. Nevertheless, MSCs have several
traits that make them well suited as carriers for IGS. Importantly, as cells that regulate im-
mune responses, MSCs have inflammation- and tumor-homing capacities, allowing them
to migrate to primary tumors, metastases, and vasculature, following inflammatory
cues [104–106]. This functionality can be of great benefit in cancer patients treated with
neoadjuvant radiotherapy, since radiotherapy induces cell injury and inflammation, mak-
ing MSCs more prone to migrate to the irradiated tumor site.
The side effects and long-term biodistribution of human MSC engraftment have
been studied in SCID and non-obese diabetic mice by Francois et al. [107]. Although the
authors did not report any side effects in this study, their group had previously demon-
strated that human MSCs could be used to help recover irradiated tissues in mice [108].
There exists some evidence that the latter also works in humans with irradiation-induced
colitis [109,110]. Additionally, MSCs offer other benefits such as hypo-immunogenicity,
amenability to autologous transplantation, relative ease of acquisition, and rapid ex vivo
expansion [111].
Furthermore, in the context of imaging, MSCs can be labeled using either or both
a radiotracer and an MR contrast agent. As an example, MSCs co-labeled with indium-
111 oxine, a clinically commonly used radioactive tracer, and ferumoxides–poly-l-lysine,
a combination of a superparamagnetic iron oxide nanoparticle and a DNA transfection
agent, allowed for in vivo biodistribution tracking, combining SPECT-CT and MRI in a
myocardial infarction mouse model [112]. Regarding NIRF imaging, Kim et al. labeled
human bone marrow-derived MSCs with fluorescent nanoparticles and subsequently
injected them systemically into glioma-bearing mice [113]. Their results indicate that
tracking using NIRF-MSCs is a feasible approach for targeting malignant gliomas, but also
that these MSCs become trapped in the lungs, liver, and spleen. One explanation for this
phenomenon is a pulmonary first-pass effect due to mechanical entrapment, owing to the
relatively large size of MSCs compared to other cells, in particular after ex vivo culture,
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with diameters ranging from 15 to 30 µm (Figure 2 and Table 1) [101]. This entrapment
occurs in vessels of small diameter, explaining the accumulation in the capillary beds
of the lungs [114]. Researchers have hypothesized that the redistribution of MSCs in
liver and spleen can be ascribed to clearance of apoptotic MSCs by phagocytic monocytes
[113–115]. Interestingly, the immunosuppressive capacity of MSCs has been linked to MSC
apoptosis and subsequent clearance by myeloid cells [115]. Regarding entrapment, not
only the large cell volume plays a role, but vascular cell adhesion molecule-1 (VCAM-
1) on the cell membrane of endothelial cells seems to be of importance in adhesion to
the pulmonary vasculature. Accordingly, inactivation of the VCAM-1 counter-ligand
on the surface of MSCs leads to an increased rate of these cells reaching the arterial
circulation [114]. In addition to this, MSCs might induce coagulation as a result of the
expression of functionally active tissue factor [116]. Although this effect must be taken into
consideration, it can easily be reversed through the administration of antithrombin therapy,
as reported by Gleeson et al. [116].
All things considered, MSCs have various assets to be a potent vehicle for IGS, es-
pecially regarding acquisition and expansion. However, entrapment of MSCs and their
coagulation-inducing properties, in addition to the earlier mentioned cell-modification-
related reactions, should all be taken into account before strategies toward clinical appli-
cations can be developed. The efficiency of target tissue imaging on the one hand and
harmful side effects on the other hand, even when treatable, must be carefully weighed
against each other.
3. Non-Cellular and Bacterial Agents for IGS
3.1. Extracellular Vesicle/Exosome-Based IGS Carriers
Extracellular vesicles (EVs) are membrane-enclosed vesicles secreted by cells.
They range from 40 nm to 5 µm in diameter, and their main function is to facilitate
intercellular communication by transferring RNA, DNA, and proteins between cells. EVs
can be divided into three subgroups: (i) exosomes, which are particles with a lipid bilayer
that are released from cells and are found in most fluids of the body (diameter: 40–100 nm;
Figure 2 and Table 1), (ii) microvesicles (MV), also known as shedding vesicles and ecto-
somes (diameter: 50 nm–1 µm), which are formed through outward budding and mem-
brane shedding, especially from transformed or injured cells, and (iii) apoptotic bodies
(diameter: 50 nm–5 µm), which are parts of the cellular content of apoptotic cells, con-
taining DNA, RNA, and histone proteins [117–119]. Given their natural functionality of
cell-to-cell transfer of biomolecules, EVs have been modified for their use as drug delivery
vehicles: for example, for the administration of anti-cancer agents in mice [120,121]. With re-
spect to imaging applications, the focus of current research lies primarily on exosomes.
Therefore, the following paragraphs will cover this topic.
In general, EVs—and exosomes in particular—have many features that make them
ideal candidates for IGS tracers. As mentioned above, they are natural carriers of sig-
nal molecules (e.g., DNA, miRNAs, siRNAs, lncRNAs, proteins, and lipids) for cell-cell
interactions [122]. Moreover, EVs offer good biocompatibility and high physiochemical
stability, permeate well through biological barriers (e.g., the blood–brain barrier), and,
when used autologously, are non-immunogenic [122,123]. Despite these features, unaltered
exosomes will, similar to most nanocarriers, accumulate in the liver, spleen, and kidney,
after administration. To address this problem, researchers have functionalized the surface
of exosomes with peptides or antibodies that target tumors. Examples of the latter are the
GE11- and EGF-positive exosomes, which Ohno et al. created for targeted miRNA delivery
to EGFR-expressing breast cancer cells in mice [124]. The exosomes were derived from hu-
man embryonic kidney 293 cells that were transfected with a mammalian expression vector
encoding GE11 or EGFR [124]. After systemic injection, the exosomes were tracked in vivo
using the lipophilic NIRF dye XenoLight DiR. However, despite their tumor-targeting
approach, the exosomes still accumulated in the liver 24 h after injection. Nevertheless,
long circulation times are not needed for intraoperative tumor imaging: a period from
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several hours up to three days would suffice. One could even argue that relatively fast
systemic clearance is beneficial for the patient, as this would both lead to an improved
tissue-to-background ratio and a reduction of possible side effects. Importantly, Ohno et al.
did not find any signs of major organ damage, which they verified by hematoxylin and
eosin staining of the liver, spleen, and kidney tissue from mice that had received the exo-
somes [124]. In the context of vascular applications, Wu et al. engineered exomes, derived
from inflammatory subtype macrophages, to target, image, and treat atherosclerotic lesions
in apolipoprotein E-deficient (ApoE−/−) mice on a high-cholesterol diet [125]. Interestingly,
these exosomes showed the same inflammation-tropism characteristics of their source cells,
which was attributed to surface-bonded chemokine receptors. Moreover, the researchers
showed that the electroporation of these exosomes with hexyl 5-aminolevulinate hydrochlo-
ride could be exploited to biosynthesize heme, which generated both anti-inflammatory
products and the red fluorescent intermediate protoporphyrin IX [125].
The most important characteristic to consider when choosing specific exosomes for any
clinical application is that the cellular lineage of a given exosome dictates its composition
and behavior. For example, exosomes derived from dendritic cells (DCs), B cells, mast
cells, or intestinal epithelial cells all express high levels of functional MHC class-I and
class-II molecules, which may elicit unwanted, MHC class-I- and class-II-restricted immune
responses in patients treated with non-autologous particles [126]. In the search of an ideal
exosome source, Tian et al. utilized exosomes derived from immature murine DCs (imDCs)
to deliver chemotherapy in murine models of cancer [127]. Specifically, they engineered
imDCs to express lysosome-associated membrane glycoprotein 2b (LAMP2b), loaded them
with doxorubicin, and then administered them intravenously to human breast tumor-
bearing BALB/c mice. The authors highlighted two critical factors behind their decision
to adopt DC-derived membrane vesicles: (i) safety, which has previously been proven in
clinical trials and (ii) the surface expression of CD9, which improves cellular drug delivery
by enabling direct membrane fusion with target cells [127].
Currently, a major hurdle for exosome usage is that there exists no consensus on
preferred purification techniques to isolate and obtain high yields of pure exosomes [128,129].
So far, the most commonly used method is ultracentrifugation. Typically, exosome yields
are less than 1 µg exosomal protein per 1 mL of culture medium [130]. In contrast, in most
mouse studies, the useful dose of exosomes ranges from 10 to 100 µg exosomal protein per
animal [130]. Therefore, the large-scale production of exosomes might be expensive [118].
However, it should be kept in mind that recent developments in the field of exosome
isolation, such as size exclusion chromatography, may significantly improve scalability and
costs in the near future [131].
To conclude, exosomes are promising targeting agents due to their natural role as
carriers of signaling molecules. Moreover, given their natural structural diversity based on
cell lineage, as well as the facility with which they can be modified at their surfaces with
targeting moieties, exosomes are amenable to custom imaging applications for tumors and
vascular diseases. Nonetheless, in order to translate the promising imaging capabilities of
exosomes into the clinic, developments in the field of isolation and purification are crucial.
3.2. Bacterium-Based IGS Carriers
Recent scientific developments have introduced the use of bacteria for cancer ther-
apy [132,133]. On average, bacterium sizes range from 0.5 to 10.0 µm (Figure 2 and Table 1),
enabling them to effectively infiltrate the human body and elicit inflammatory responses.
Multiple species of anaerobic bacteria are known to colonize and replicate in hypoxic
and necrotic regions of tumors, including species from the Salmonella, Bifidobacterium, and
Clostridium genera [134,135]. Bacteria can be easily genetically manipulated in order to
express (non-)human and fluorescent proteins of choice. In an ideal situation, one could
envision a wide gamut of bacteria functioning as IGS tracers, in which context the species
would be chosen according to its specificity for a type of tumor or cardiovascular lesion.
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Intriguingly, whole bacteria have been used in tumor immunotherapy; However, they
can be pathogenic and cause adverse reactions in healthy tissue. Thus, any bacterium used
as a carrier for imaging agents would have to be completely non-pathogenic and non-toxic.
One way to ensure this would be to use naturally non-pathogenic strains such as those
found in common food products. Along these lines, Miyaguchi and colleagues reported
that the direct injection of Lactobacillus casei, which is found in the human gut as well as
in many fermented foods, into murine models of cancer provoked a reduction in tumor
growth relative to untreated controls [136]. Importantly, they did not find the bacterium in
any healthy tissue. In humans, a successful example of the use of mycobacteria in cancer
is the bacillus Calmette–Guérin (BCG) therapy used for bladder cancer. BCG therapy has
been used as a treatment for non-muscle-invasive bladder cancer for more than 30 years.
BCG therapy is highly effective in early stage bladder cancer and has a preventative effect
on postoperative recurrence [137]. It is thought that the anti-tumor activities of BCG are
caused by activation of the immune system and subsequent inducement of inflammatory
responses. However, this anti-tumor effect is also associated with genitourinary side
effects such as chemical cystitis (35%), bacterial cystitis (23.3%), macroscopic hematuria
(22.6%), and with systemic complications such as persistent high-grade fever (2.9%) [138].
These undesired effects presumably stem from the body’s inflammatory response to BCG
and are most likely induced by the process of inflammation. Therefore, inflammation is
seen as a double-edged sword in the field of bacterium-based therapies or carriers, entailing
an important pathogenic mechanism as well as generating a potent anti-tumor effect.
The therapeutic use of bacteria, even in the case of carefully selected attenuated
strains, generally involves risk of adverse events. This is especially true with systemic
administration of bacteria, which can provoke hyperimmune reactions (e.g., cytokine
storm) with severe consequences for patients, including death [135]. Logically, before any
patient is treated with bacteria, caregivers must ensure that species-specific antibiotics are
available for immediate use upon any sign of harmful (immune) responses.
An advantage of using bacteria for therapeutics as well as imaging is that bacterial
culture systems have been used for decades, which translates to existing infrastructure,
well-established manufacturing processes, and low costs [135]. There have been numerous
studies on bacteria-based imaging. For instance, Berlec et al. established fluorescence in
bacteria by expressing the infrared fluorescent protein IRFP713 in three bacterial species
(Lactobacillus plantarum, Lactococcus lactis, and Escherichia coli), subsequently administered
the bacteria to mice, and then monitored the live bacteria in the intestinal tracts of the
animals [139]. Expression of an additional protein, IRFP682, enabled concomitant near-
infrared detection of two different bacterial populations within a single mouse via spectral
unmixing. As with bacterial therapeutics, bacterial imaging agents present risks of adverse
immune responses in patients. For example, the host immune response can clear the
bacteria from the bloodstream, precluding them from colonizing the tumor site at detectable
levels [140]. In addition to the selective removal of virulence factors and use of antibiotics,
a solution to hyperimmune reactions could lie in genetically manipulating bacteria in order
to be replication deficient upon the absence of specific nutrients. A noteworthy example is
the A1-R Salmonella strain, which is known for its anti-tumor effects, accumulation at tumor
sites, and which is auxotrophic for arginine and leucine [141]. Potentially, auxotrophy
could be employed to locally stimulate bacteria to replicate, which would increase the
tissue-to-background ratio and simultaneously decrease the number of bacteria that need to
be injected. Regarding radiolabeling of bacteria, multiple species have been traced in vivo,
including technetium-99m-labeled Escherichia coli and 8-3H-adenine-labeled Salmonella
typhimurium [142,143].
In conclusion, bacteria have distinctive advantageous properties compared to other
cell-based targeting agents. Specifically, low production costs, a variety of suitable species,
ease of manipulation and culturing, and selective replication in tumors together suggest
great potential for bacterium-based imaging. However, since bacteria are microorganisms
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that could elicit destructive immune responses, vigilance should be maintained throughout
their development, implementation, and clinical use.
3.3. Virus-Based IGS Carriers
Although not regarded as living, viruses are ideal candidates for tumor imaging con-
sidering their specificity, small diameter (5–400 nm), and ability to self-replicate. Oncolytic
virus therapy, whereby cancer patients are deliberately infected with viruses that selectively
kill malignant cells and spare heathy tissue, is a promising therapeutic approach [144].
The viruses used in this context are naturally occurring strains that are sometimes geneti-
cally modified. These viruses are specifically directed against cancer tissue and replicate
within tumor cells to produce viral progeny. Thus, the virus itself acts as an active drug.
A noteworthy example is the glioma-specific Herpes simplex type 1 amplicon virus (SU4-
124 HSV-1) used by Delwar et al. [145]. They reported that the virus exhibited strong
anti-tumor effects against glioma cell lines in vitro and, in mice bearing human glioma U87
tumors, after intratumoral injection. Importantly, no viral DNA was detected in healthy
tissue.
A major concern that is generally associated with the use of viruses for therapy
or diagnosis is that common, naturally occurring viruses that lead to viremia are likely
to trigger the production of neutralizing antibodies in the patient via memory-induced
immunity. However, this would not be an issue with viral agents used for (pre)operative
targeted imaging in IGS, as the virus would be administered to the patient shortly before
surgery for short-term use only (a few minutes to several hours). Namely, the patients’
anti-viral immune responses would require at least a couple of days to reach peak intensity.
One could even argue that these immune responses favor the patient in terms of toxicity,
since the mechanism will ensure removal of the virus from the circulation. Next to that,
anti-viral agents, when available and effective against a specific viral strain, could be easily
administered directly after the clinically needed effect, ensuring safety. Nevertheless, it
should be kept in mind that these anti-viral agents are not available for and effective against
all virus species (e.g., variable anti-viral activity against adenoviruses).
Adenoviruses or adeno-associated viruses that are used as vectors for gene therapy
can be adopted as a delivery system for macromolecules other than DNA, including for
the delivery of imaging agents to tumors, owing to the amenability of their capsids to
surface modification [144]. For instance, Shan and co-authors functionalized adenovirus
capsids with folate to enhance the viruses’ natural ability to target tumors that express
low levels of Coxsackie-adenovirus receptor [146]. The authors attributed this effect to
the increase in expression of folate receptors in cancer cells of malignant tumors during
proliferation and cellular activation (e.g., cancers of the brain, lung, testis, kidney, colon,
myelocytic blood cells, and liver) [146]. They also attached the NIRF dye ICG-Der-02 to
their modified adenovirus, which allowed for in vivo fluorescence imaging. Furthermore,
the authors hypothesized that it should be possible to extend the targeting capability of
adenoviruses by other chemical modifications of its capsid [146]. Spronken et al. engineered
five different reporter viruses of the influenza A virus, including one that was transfected
with a near-infrared fluorescent protein [147]. Moreover, Hofherr et al. succeeded in the
real-time tracking of intravenously injected adenoviruses with a near-infrared fluorophore
in mice [148]. They preclinically administered the clinically used fluorophore IRDye800CW
in a concentration of 10,000–100,000 dye molecules per viral particle. The fact that they
performed the dye-coupling reaction at room temperature for only 1 hour suggests that their
approach would be feasible in a clinical setting. In the context of SPECT-CT, it was shown
by Stella Man et al. that systemically administered Iodine-125-labeled oncolytic adenoviral
mutants could be monitored in real time using murine pancreatic cancer models [149].
The researchers designed a radiolabeling procedure with optimized conditions, retaining
the adenoviral tumor-targeting functions.
Everything considered, the combination of their ease of modifiability, ability to repli-
cate, specificity, and variety in suitable species render viruses as interesting candidates
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for IGS targeting agents. However, two important considerations should be made when
choosing a specific virus species to focus on in further research: (i) there should be either
an effective anti-viral agent available or an eliminated risk of adverse (immune) responses,
and (ii) the individual patients’ immune reaction against the specific virus should be within
reasonable margins, without prematurely neutralizing the virus’ imaging capabilities.
In general, when considering current developments, the immunogenicity of viruses should
not be a major concern for short-term imaging applications such as IGS.
4. Synthetic Nanoparticles for IGS
Synthetic nanoparticles such as liposomes, dendrimers, and carbon nanotubes have
been designed for the targeting of tumors at multiple sites [150]. These particles are
substantially larger (Figure 2 and Table 1) than molecular targeting agents such as peptides
(≈1 nm) and IgG antibodies (10 nm) [151], and they are not as flexible as living cells,
but they are still able to enter endothelial pores (fenestrae ≈10 nm–2 µm) and penetrate
(tumor) tissues efficiently [152]. This phenomenon is partly attributed to the enhanced
permeability and retention (EPR) effect, by which neoangiogenic vasculature favors the
permeability and retention of extravascular molecules within the stroma. Nanoparticles
can be engineered with a high level of control to perform physiological tasks such as
the delivery of drugs or dyes to tumors [151]. The size of nanoparticles influences their
distribution in tissue; thus, larger nanoparticles (50–200 nm) tend to have greater passive
accumulation at tumor sites but less efficient penetration into the tumor, whereas smaller
nanoparticles (<50 nm) penetrate easily into the tumor but are more rapidly eliminated
from the circulation. Common disadvantages of nanoparticles include rapid clearance
by macrophages and the liver (within three to five hours), a need for large numbers of
nanoparticles for effective tumor labeling, high production costs, and limitations on the
amount of targeting agents that can be added to the surface [92,153]. As synthetic objects,
nanoparticles are neither living nor cell-derived. However, they can be coated with the
membranes of cells of various origins. Therefore, we will include a short overview of the
most relevant types of nanoparticles and their application for imaging purposes.
Liposomes are nanoparticles enclosed by a modifiable lipid-bilayer membrane, which
enables them to carry both hydrophobic and hydrophilic cargo, potentially bypass the
reticuloendothelial system (by which phagocytic cells remove immunogenic particles from
the circulation), and undergo surface functionalization. Examples of liposomes used for
targeted therapies include work by the group of Basel, who modified liposomes with
peptides that specifically target metastases and reported the superior targeting and efficacy
of metastases compared to highly metastatic primary tumors [154,155]. Interestingly, Li
and Huang demonstrated that the uptake of liposomes by the reticuloendothelial system
can be diminished and, consequently, accumulation of them in tumors increased by first
adding a second bilayer to the liposomes and then functionalizing those with PEGylated
lipids [156]. They also reported that this modification confers the liposomes with greater
stability, minimal protein binding, and a neutral charge.
Dendrimers are nanoparticles comprising a central core and repeated branches with
terminal functional groups. Their distinct tree-like shape, molecular weight range, and
constitution provide them with unique features. For instance, dendrimers can carry drugs
or dyes through encapsulation or via binding by electrostatic or hydrophobic/hydrogen
bonds. Their main advantage is that they are assembled stepwise, enabling researchers to
selectively introduce structural modifications for desired functionalities. The tumor cells
can be targeted either by employing the EPR effect, by specific terminal functional groups
(e.g., peptides or antibodies), or even a combination of the two [157]. An interesting ex-
ample of employing dendrimers for tumor-targeting was reported by Sunoqrot et al., who
encapsulated folate receptor-targeting polydendrimers into larger polyethylene glycol-poly
lactic acid (PEG-PLA) polymeric nanoparticles [158]. The resultant dendrimer/nanoparticle
hybrid platform executed controlled release of the folate receptor-targeting dendrimers
in mice that bore folate receptor-overexpressing tumors. Importantly, the dendrimer–
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nanoparticle hybrid prevented premature renal elimination of the dendrimers in vivo,
which is a problem that occurred when the free dendrimers had been administered. The au-
thors expected that their folate receptor-targeting dendrimer–nanoparticle hybrid platform
would exhibit superior targeting relative to that of basic polymeric nanoparticles.
Carbon nanotubes (CNTs) are hollow tubes of single or multilayered graphene whose
structure confers them with high capacity for the delivery of bioactive agents and dyes.
While the length and structure of CNTs depend on their design, both practical and the-
oretical studies have shown that the smallest possible carbon nanotube has a diameter
of 3–4 Å [159–161]. The main downsides of CNTs are their high toxicity, poor solubility,
and tendency to agglomerate, all of which limit their utility in clinical practice. A solution
could be coating their exterior. CNTs are able to form covalent or non-covalent bonds
with biological and bioactive species of chemical agents to become more soluble and less
immunogenic. Their surface binding potential enables them to bind to targeting agents or
other compounds of functional interest [162]. Wu and Zhao generated composites from
single-walled CNTs (SWCNTs) and natural biopolymers for targeted imaging of cancer
cells, showing that these composites provided an alternative to existing unbound dyes [163].
These nanoprobes (PPa/fluorescein isothiocyanate (FITC)-SWCNT-Folate), which target fo-
late receptor-positive tumor cells, demonstrated good targeting and photodynamic therapy
performance [163].
The field of nanoparticles for IGS is too rapidly expanding to be fully covered in this
review, but its innovative nature is particularly illustrated by the following two examples.
Vankayala et al. effectively imaged intraperitoneal ovarian tumors in mice using NIRF dye-
labeled, virus mimicking nanoparticles, which were derived from genome-depleted mosaic
viruses and were functionalized with anti-HER2 antibodies [164]. Schmidt et al. reviewed
the characteristics of microrobots, which are motile microsystems that are designed to reach
their targets after physical, biological, or chemical alterations [165]. Microrobots are highly
engineerable and may consist of cell-made, synthetic, and hybrid components. This allows
for a direct and active targeting potential via specific accumulation (e.g., mediated by
active sensing of the (micro)environment) and increased penetration of healthy as well as
diseased tissue.
5. Discussion and Overall Conclusions
Targeted imaging of pathologic lesions is an effective tool to enhance the visual
capabilities of surgeons during operations. Cells, cell fragments, microorganisms, and
nanoparticles, which have been labeled with NIRF dyes (e.g., ICG and IRDye800CW)
MRI labels (e.g., magnetic beads), or radioactive labels (e.g., indium-111 oxine and 18F-
FDG), might offer several advantages in comparison to currently used agents, as they can
actively target lesion sites, penetrate target tissues, and interact with dynamic environments.
Autologous cells, as well as platelets or other cell fragments, have the advantage that
they are non-immunogenic, enabling them to avoid both unwanted immune responses
and rapid removal from the circulation in treated patients. Although the use of any
microorganism implies certain risks associated with immunogenicity, they also offer some
specific advantages. For example, bacteria can be easily grown and selected/manipulated,
and viruses are very small and readily modified, enabling them to target tumor sites with
higher specificity than other agents. Platelets also excel at targeting both vascular and
oncologic pathologies, which is mainly due to their size and natural tendency to bind to
factors related to tumor tissue and damaged endothelial cells.
Regardless of the potential of any given new cellular or cell-derived tracer for IGS,
a decisive factor for exploration is the feasibility of translating that potential into the
clinic. In this sense, some of the presented modalities are facing issues in terms of balance
between risk for the patient and benefit for IGS results. Research within the field of cell-
based IGS has mainly focused on proof of principle preclinical experiments, while more
translational research is needed to demonstrate the benefits of active targeting. Together
with obvious disadvantages, such as the possibility of unwanted immune reactions by using
Int. J. Mol. Sci. 2021, 22, 755 18 of 26
bacteria or viruses and the immaturity and costs associated with production processes
of autologous cell-based carriers, the adoption of this novel type of IGS tracer in the
clinic will rely on both the support of clinicians and sufficient funding. In a later stage,
another problem may arise in terms of applicability. Even when properly developed
and affordable, the usage of different cell-based carriers for every specific combination
of tumor type and patient characteristics will severely impair its ability to get adopted
into the market. Regarding the latter, the different modification steps needed in some
of the applications, such as purification or isolation, could add to its cumbersomeness
and question its efficiency. Moreover, the risk of adverse immune reactions should not be
considered lightly, since it will both add to the complexity of patient-specific treatment and
accessory costs. In that respect, IGS will probably depend on the rapid developments in
cell-based therapy.
Whilst one could argue that, with time, the general expenses of any specific technique
decrease, the many factors that influence costs must be considered. Development processes
could be drastically advanced, especially when other clinical research fields simultaneously
drive the development of certain techniques. Therefore, the translation of new ISG tracers
into the clinic will require that they are embraced, promoted, and co-developed by clinicians.
The establishment of multidisciplinary research groups that bridge the implementation
gap by drawing on the preclinical and clinical expertise of diverse professionals is essential.
Furthermore, together with the development of novel implementations, early adoption
and clinical use will increase demand, thereby facilitating acquisition of sufficient funding
for the required experiments to regenerate the development cycle.
Currently, tracers for IGS are based on the targeting of a single protein by a labeled
peptide or antibody. In the future, an ideal situation for new targeted tracers in IGS would
be one of choice, in which the appropriate agent would be selected and modified based
on the type of cancer or vascular lesion, also taking into account its anatomic location,
any relevant comorbidities, and patient preferences. To achieve this, the development and
evaluation of multiple types of cell-based targeting agents should help ensure success for
patients, clinicians, and researchers, as such agents can inform each other and might even
be used concomitantly for increased accuracy. While the risk–benefit ratio of cell-based IGS
still needs to be carefully weighed, the field is still in its infancy and has enormous potential.
There are many other possibilities to develop new tracers for IGS beyond those that we
have reviewed here. A non-obvious but fascinating choice for targeted imaging are the
algae-based systems as recently developed by Qiao and coworkers [166]. Therefore, and
referring to other famous explorations, we regard image-guided surgery as one of the most
exciting and clinically translational fields in future medicine and are proud to participate
in “a mission to explore novel targets and develop new tracers, and to boldly go where no
man (or tracer) has gone before [167].”
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